Nebivolol: A third-generation β-blocker for hypertension

JWM Cheng - Clinical therapeutics, 2009 - Elsevier
Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Nebivolol: A third-generation β-blocker for hypertension

JWM Cheng - Clinical Therapeutics, 2009 - infona.pl
Background: Nebivolol is a third-generation β 1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

[引用][C] Nebivolol: A Third-Generation β-Blocker for Hypertension

JWM CHENG - Clinical therapeutics, 2009 - pascal-francis.inist.fr
Nebivolol : A Third-Generation β-Blocker for Hypertension CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …

Nebivolol: A third-generation β-blocker for hypertension

JWM Cheng - Clinical Therapeutics, 2009 - clinicaltherapeutics.com
Background: Nebivolol is a third-generation β 1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Nebivolol: a third-generation beta-blocker for hypertension

JWM Cheng - Clinical therapeutics, 2009 - pubmed.ncbi.nlm.nih.gov
Background Nebivolol is a third-generation beta (1)-selective beta-blocker that is approved
for the treatment of hypertension. Objective This article reviews the clinical pharmacology of …

Nebivolol: a third-generation beta-blocker for hypertension.

JW Cheng - Clinical Therapeutics, 2009 - europepmc.org
Background Nebivolol is a third-generation beta (1)-selective beta-blocker that is approved
for the treatment of hypertension. Objective This article reviews the clinical pharmacology of …

[引用][C] Nebivolol: A third-generation [beta]-blocker for hypertension

JWM Cheng - Clinical Therapeutics, 2009 - Elsevier Limited

[引用][C] Nebivolol: A Third-Generation β-Blocker for Hypertension

JWM CHENG - Clinical therapeutics, 2009 - Elsevier